Literature DB >> 3556665

Ocular morbidity after radiotherapy of orbital and conjunctival lymphoma.

E M Bessell, J M Henk, R A Whitelocke, J E Wright.   

Abstract

One hundred and fifteen patients were treated for lymphoma of the conjunctiva and orbit between 1970 and 1984. One hundred and twelve patients received radiotherapy to the orbit, of whom 73 (65 per cent) had at least one year of follow-up by an ophthalmic surgeon. Patients with low-grade lymphomas (97) mostly received 30 Gy in 15 fractions to the orbit over a period of 3 weeks. Those with high-grade lymphomas (18) mostly received 40 Gy in 20 fractions over 4 weeks. Most were treated using anterior and lateral radiation fields to the orbit with shielding of the cornea and lens. This technique delivered a mean lens dose of 15 Gy. The early and late ocular and orbital morbidity in these patients was low. Eight radiation-induced cataracts developed of which only six interfered with vision. None has needed cataract surgery. No patients developed radiation retinopathy and only 5 had disorders of ocular lubrication.

Entities:  

Mesh:

Year:  1987        PMID: 3556665     DOI: 10.1038/eye.1987.14

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  15 in total

1.  Interferon treatment of childhood conjunctival lymphoma.

Authors:  R S Lucas; R Mortimore; T J Sullivan; M Waldie
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  Subconjunctival corticosteroids for benign lymphoid hyperplasia.

Authors:  D G Telander; T Z Lee; S E Pambuccian; A J W Huang
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

Review 3.  Retrospective study and review of ocular radiation side effects following external-beam Cobalt-60 radiation therapy in 37 dogs and 12 cats.

Authors:  Chantale L Pinard; Anthony J Mutsaers; Monique N Mayer; J Paul Woods
Journal:  Can Vet J       Date:  2012-12       Impact factor: 1.008

4.  Intra-lesional interferon injection for recurrent conjunctival MALT lymphoma.

Authors:  M Zayed; K Sears; S M Salvi; P A Rundle; I G Rennie; H S Mudhar
Journal:  Eye (Lond)       Date:  2013-04-05       Impact factor: 3.775

5.  Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato; Akiko Yamane; Yoshinobu Aisa; Yusuke Kawata; Mayu Ichimura; Chiaki Tsuneyama; Tomoko Yashima; Yoko Ogawa; Kazuo Tsubota; Naoyuki Shigematsu; Takayuki Shimizu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-08-19       Impact factor: 2.490

6.  A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study.

Authors:  Matthew M Ladra; Samantha K Edgington; Anita Mahajan; David Grosshans; Jackie Szymonifka; Fazal Khan; Maryam Moteabbed; Alison M Friedmann; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Radiother Oncol       Date:  2014-10-16       Impact factor: 6.280

7.  [Principles of radiation therapy for malignant tumors of the orbit and the periorbital area].

Authors:  T Kuhnt; M Janich
Journal:  HNO       Date:  2010-01       Impact factor: 1.284

8.  A case of radiation retinopathy of left eye after radiation therapy of right brain metastasis.

Authors:  Kwon Ho Hong; Sung Dong Chang
Journal:  Korean J Ophthalmol       Date:  2009-06-09

9.  Recovery of radiation-induced dry eye and corneal damage by pretreatment with adenoviral vector-mediated transfer of erythropoietin to the salivary glands in mice.

Authors:  Eduardo M Rocha; Ana P Cotrim; Changyu Zheng; Paola Perez Riveros; Bruce J Baum; John A Chiorini
Journal:  Hum Gene Ther       Date:  2013-04       Impact factor: 5.695

10.  Clinical course and pathologic features of conjunctival non-Hodgkin's lymphoma. A report of six cases.

Authors:  H A Khalil; R J de Keizer; P M Kluin; H C Kluin-Nelemans; D de Wolff-Rouendaal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.